(Adnkronos) - Con una produzione che nel 2023 ha superato per la prima volta i 50 mld di euro, 3.6 mld di investimenti in innovazione e un numero crescente di brevetti, il settore farmaceutico Italiano rappresenta un unicum in Europa e ha un ruolo chiave per il nostro Paese. L’eccellenza farmaceutica italiana può attrarre investimenti ed essere un forte stimolo per la competitività italiana in Europa e nel mondo, ma serve una strategia. Se ne è parlato a Roma, durante l’incontro “Il valore del settore farmaceutico nel sistema Paese. Una Life Sciences strategy italiana”, promosso da Sanofi Italia a Roma, presso il Centro Studi Americani dove istituzioni
Category
🗞
NewsTranscript
00:00With a production that in 2023 exceeded 50 billion euros for the first time,
00:103.6 billion investments in innovation and a growing number of patents,
00:15the Italian pharmaceutical sector represents a unique one in Europe
00:19and has a key role for our country.
00:22Italian pharmaceutical excellence can be a powerful magnet capable of attracting investments
00:27and a strong stimulus for Italian competitiveness in Europe and in the world.
00:31We spoke about it in Rome during the meeting
00:34The Value of the Pharmaceutical Sector in the Country System,
00:37an Italian life-science strategy,
00:40promoted by Sanofi Italia in Rome at the Centro Studi Americani,
00:44where institutions, experts and companies met to build together
00:49a life-science development strategy.
00:52A strategic partner for the economy, employment,
00:55the development of innovation and the growth of our country.
00:58Today we wanted to promote a meeting dedicated to the strategic value
01:03that the pharmaceutical sector brings to the country system,
01:07with a deepening, thanks also to the collaboration with the Institute of Research VIFOR,
01:12precisely on the data that Sanofi brings, the impact that Sanofi brings to the country.
01:18In particular, significant data emerged,
01:211.4 billion in terms of contribution to the PIL,
01:26but also in terms of value that every job in Sanofi generates in the country system,
01:35with a multiplier of more than 5.
01:39Also important data on the R&D intensity of 3%.
01:46Italy will play a fundamental role also in clinical research.
01:51All this is important, but what we want to do today is to launch an appeal,
01:57an appeal to the country because it is endowed with a comprehensive life-science strategy
02:07of various aspects, where precisely the life-science sector
02:12is placed at the center of the development of this country.
02:15According to the latest analysis of the Technology Forum Life Science
02:19promoted by The European House Ambrosetti,
02:22Italy is placed in the middle-high innovation range,
02:26but remains distant from the top performers.
02:28Today Italy is positioned for direct foreign investment
02:32behind Germany, France and Spain.
02:36In Europe, we have seen over the years that other countries
02:40have equipped themselves with a real vision and life-science strategy.
02:44A structured plan of interventions and an integrated policy
02:49that can also involve other ministries.
02:52So let's also think about research policies, health policies,
02:56which are fundamental in a system in which this sector wants to be valued.
03:00A sector that is important, that gives a contribution of more than 2% of the GDP to our country.
03:07And if we only look at the share of multinationals in foreign capital
03:10that join APG and Unifarma, we are talking about about 20 billion euros
03:15of direct, indirect and inductive contribution.
03:18More than 1% of GDP.
03:20A value that can certainly increase,
03:22which can therefore help to accelerate the recovery and economic growth
03:26that our country needs.